Clinical trials: Invasive Group A Beta-Haemolytic Streptococcal Disease
Streptococcal Sepsis, Invasive Group A Beta-Haemolytic Streptococcal Disease
Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections
This study aims to emulate a hypothetical target pragmatic multi-center, non-blinded trial of adult inpatients in the PINC AITM dataset with B-lactam treated culture confirmed monomicrobial invasive Group A streptococcus (GAS)…
- Conditions
- Streptococcal Sepsis, Invasive Group A Beta-Haemolytic Streptococcal Disease, Necrotizing Soft Tissue Infection, Infection, Bloodstream
- Trial name
- iGASAntitox (NCT06126263)
- Testing
- Linezolid, Clindamycin
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Invasive Group A Beta-Haemolytic Streptococcal Disease
Paediatric European Group A Streptococcal United Study.
Introduction Since 2022 there are reports of a rapid increase in invasive group A streptococcal infections (iGAS) in children in some but not all European countries. Detailed information on this increase is lacking.
- Trial name
- PEGASUS (NCT06058117)
- Testing
- No intervention
- Where
- Netherlands
- Volunteers
- 500 people
- Sponsor
- Noordwest Ziekenhuisgroep
Invasive Group A Beta-Haemolytic Streptococcal Disease
Invasive Disease Caused by Group A Streptococcus (GAS) (DICAR)
The goal of this study is to gain important knowledge on the pathogenesis and prognostic factors in severe invasive group A streptococcal (GAS) infections, as well as the effects of individual characteristics of both the pathogen…
- Trial name
- DICAR (NCT03507101)
- Testing
- No intervention
- Where
- 2 sites in Finland
- Volunteers
- 45 people
- Sponsor
- Tampere University Hospital
Invasive Group A Beta-Haemolytic Streptococcal Disease
Severe Group A Streptococcus Infections in Paris, France, 2018-2023
Streptococcus pyogenes, commonly referred to as Group A Streptococcus (GAS), has the ability to induce a diverse range of illnesses.
- Trial name
- IGASI (NCT06297122)
- Testing
- Collection of data from the patient's medical file
- Where
- France
- Volunteers
- 269 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris